{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:44:33Z","timestamp":1770453873335,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Janssen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s15010-020-01428-1","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T15:04:05Z","timestamp":1589209445000},"page":"453-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study"],"prefix":"10.1007","volume":"48","author":[{"name":"for the PROPHET study group of dagnae e.V.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6737-5104","authenticated-orcid":false,"given":"Markus","family":"Bickel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-8520","authenticated-orcid":false,"given":"Eva","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Baumgarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-5473","authenticated-orcid":false,"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-5367","authenticated-orcid":false,"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Postel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3625-9650","authenticated-orcid":false,"given":"Stefan","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Preis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Klauke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knud","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"1428_CR1","unstructured":"Deutsche AIDS-Gesellschaft, \u00d6sterreichische AIDS-Gesellschaft. Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. https:\/\/daignet.de\/site-content\/hiv-leitlinien\/hiv-leitlinien. Accessed Nov 2019."},{"key":"1428_CR2","unstructured":"EACS. European Guidelines for treatment of HIV-positive adults in Europe 10.0. https:\/\/www.eacsociety.org\/files. Accessed Nov 2019."},{"key":"1428_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/QAD.0000000000002077","volume":"33","author":"A Carr","year":"2019","unstructured":"Carr A, Richardson R, Liu Z. Success and failure of initial antiretroviral therapy in adults: an updated systematic review. AIDS. 2019;33:443\u201353.","journal-title":"AIDS"},{"key":"1428_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s15010-016-0880-4","volume":"44","author":"G Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer G, Kreuels B, Schmiedel S, Hertling S, H\u00fcfner A, Degen O, van Lunzen J, Schulze Z, Wiesch J. High proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany: time to put better HIV screening efforts on the national agenda? Infection. 2016;44:347\u201352.","journal-title":"Infection"},{"key":"1428_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s15010-018-1248-8","volume":"47","author":"M Stecher","year":"2019","unstructured":"Stecher M, Schommers P, Schmidt D, Kollan C, Gunsenheimer-Bartmeyer B, Lehmann C, Platten M, F\u00e4tkenheuer G, Vehreschild JJ, ClinSurv Study Group. Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. Infection. 2019;47:247\u201355.","journal-title":"Infection"},{"key":"1428_CR6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/QAD.0000000000001708","volume":"32","author":"EF Eaton","year":"2018","unstructured":"Eaton EF, Tamhane A, Davy-Mendez T, et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS. 2018;32:347\u201355.","journal-title":"AIDS"},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/QAI.0000000000001481","volume":"76","author":"T Davy-Mendez","year":"2017","unstructured":"Davy-Mendez T, Eron JJ, Zakharova O, Wohl DA, Napravnik S. Increased persistence of initial treatment for hiv infection with modern antiretroviral therapy. J Acquir Immune Defic Syndr. 2017;76:111\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1428_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15284336.2018.1440691","volume":"19","author":"A d\u2019Arminio Monforte","year":"2018","unstructured":"d\u2019Arminio Monforte A, Lorenzini P, Cozzi-Lepri A, et al. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials. 2018;19:52\u201360.","journal-title":"HIV Clinical Trials"},{"key":"1428_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/15284336.2017.1387690","volume":"18","author":"E Lathouwers","year":"2017","unstructured":"Lathouwers E, Wong EY, Luo D, Seyedkazemi S, De Meyer S, Brown K. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. HIV Clin Trials. 2017;18:196\u2013204.","journal-title":"HIV Clin Trials"},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1093\/jac\/dkw343","volume":"71","author":"K El Bouzidi","year":"2016","unstructured":"El Bouzidi K, White E, Mbisa JL, et al. HIV-1 drug resistance mutations emerging on darunavir therapy in PI naive and -experienced patients in the UK. J Antimicrob Chemother. 2016;71:3487\u201394.","journal-title":"J Antimicrob Chemother"},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/hiv.12581","volume":"19","author":"JR Santos","year":"2018","unstructured":"Santos JR, Cozzi-Lepri A, Phillips A, et al. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. HIV Med. 2018;19:324\u201338.","journal-title":"HIV Med"},{"key":"1428_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s15010-016-0911-1","volume":"44","author":"AJ Zeder","year":"2016","unstructured":"Zeder AJ, Hilge R, Schrader S, Bogner JR, Seybold U. Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate. Infection. 2016;44:641\u20139.","journal-title":"Infection"},{"key":"1428_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/hiv.12562","volume":"19","author":"J Young","year":"2018","unstructured":"Young J, Smith C, Teira R, et al. Antiretroviral pill count and clinical outcomes in treatment-na\u00efve patients with HIV infection. HIV Med. 2018;19:132\u201342.","journal-title":"HIV Med"},{"key":"1428_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/hiv.12695","volume":"20","author":"DC Griffith","year":"2019","unstructured":"Griffith DC, Farmer C, Gebo KA, et al. Uptake and virological outcomes of single-versus multi-tablet antiretroviral regimens among treatment-na\u00efve youth in the HIV Research Network. HIV Med. 2019;20:169\u201374.","journal-title":"HIV Med"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"1428_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1310\/hct1506-261","volume":"15","author":"SL Li","year":"2014","unstructured":"Li SL, Xu P, Zhang L, Sun GX, Lu ZJ. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis. HIV Clin Trials. 2014;15:261\u20138.","journal-title":"HIV Clin Trials"},{"key":"1428_CR17","first-page":"56","volume":"17","author":"JM Llibre","year":"2015","unstructured":"Llibre JM, Pulido F, Garc\u00eda F, Garc\u00eda Deltoro M, Blanco JL. Delgado R Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17:56\u201364.","journal-title":"AIDS Rev"},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/jac\/dky566","volume":"74","author":"A d'Arminio Monforte","year":"2019","unstructured":"d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, et al. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019;74:1363\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"1428_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QAI.0000000000002075","volume":"81","author":"RM Nance","year":"2019","unstructured":"Nance RM, Vannappagari V, Smith K, et al. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019;81:572\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1428_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s15010-016-0936-5","volume":"45","author":"A Zoufaly","year":"2017","unstructured":"Zoufaly A, Kraft C, Schmidbauer C, Puchhammer-Stoeckl E. Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013. Infection. 2017;45:165\u201370.","journal-title":"Infection"},{"key":"1428_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40271-016-0195-7","volume":"10","author":"K Engler","year":"2017","unstructured":"Engler K, Lessard D, Lebouch\u00e9 B. A review of HIV-specific patient-reported outcome measures. Patient. 2017;10:187\u2013202.","journal-title":"Patient"},{"key":"1428_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/QAD.0000000000001417","volume":"31","author":"AR Lifson","year":"2017","unstructured":"Lifson AR, Grund B, Gardner EM, et al. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS. 2017;31:953\u201363.","journal-title":"AIDS"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-020-01428-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T01:16:34Z","timestamp":1620695794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-020-01428-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s15010-020-01428-1","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"8 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Markus Bickel has received honoraria for lecturing from the Hess.Arbeitsgemeinschaft der HIV-Versorger (HIVAG), travelling grants from Deutsche Arbeitsgemeinschaft niedergelassener \u00c4rzte in der Versorgung HIV-Infizierter e. V. (dagn\u00e4) and has received research grants from AbbVie, Janssen-Cilag, MSD, Gilead Sciences, Glaxo Smith Kline, dagn\u00e4, Deutsche Leberstiftung, Institut f\u00fcr HIV Forschung Universit\u00e4tsklinikum Essen, Infektionsmedizinisches Zentrum Hamburg (ICH). Christian Hoffmann has received honoraria for lecturing, advisory boards and\/or travelling grants from AbbVie, EusaPharm, Gilead Sciences, HEXAL, Hormosan, Janssen-Cilag, MSD and ViiV Healthcare; he has also received research grants from AbbVie, Janssen-Cilag, MSD and Gilead Sciences. Stephan Klauke has received travelling grants from Deutsche Arbeitsgemeinschaft niedergelassener \u00c4rzte in der Versorgung HIV-Infizierter e. V. (dagn\u00e4) and has received research grants from AbbVie, Janssen-Cilag, MSD, Gilead Sciences, Glaxo Smith Kline, dagn\u00e4, Deutsche Leberstiftung, Institut f\u00fcr HIV Forschung Universit\u00e4tsklinikum Essen, Infektionsmedizinisches Zentrum Hamburg (ICH). Christoph D. Spinner has received grants for travel and participation in advisory boards or speaker\u2019s honoraria from AbbVie, Astellas, Bristol-Meyers Squibb, Gilead, Janssen-Cilag, MSD, and ViiV Healthcare. He has also received grants for investigator-sponsored studies from Gilead Sciences, Janssen-Cilag, and ViiV Healthcare. Eva Wolf has received grants for travel and participation in advisory boards or speaker\u2019s honoraria from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, MSD Sharp & Dohme, Roche, and ViiV Healthcare. Knud Schewe has received speakers honoraria as well as honoraria for advisory boards and\/or travel grants from AbbVie, Gilead Sciences, HEXAL, Janssen-Cilag, MSD and ViiV Healthcare as well as travel grants and conference sponsoring from Deutsche Arbeitsgemeinschaft niedergelassener \u00c4rzte in der Versorgung HIV-Infizierter e. V. (dagn\u00e4). Axel Baumgarten has received honoraria for lecturing, advisory boards and\/or travelling grants from AbbVie, Gilead Sciences, Janssen, Sanofi, MSD and ViiV Healthcare. Stefan Esser has received honoraria for lecturing, advisory boards and\/or travelling grants from AbbVie, Gilead Sciences, HEXAL, Janssen-Cilag, MSD and ViiV Healthcare; he has also received research grants from ViiV, Janssen-Cilag, MSD and Gilead Sciences. Christoph Wyen has received grants for travel and participation in advisory boards or speaker\u2019s honoraria from AbbVie, Bristol-Meyers Squibb, Gilead, Janssen-Cilag, MSD, and ViiV Healthcare. On behalf of all other authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The primary ethical approval was received by the University Duisburg\/Essen on June 25, 2014 (ID 14-5847-BO), the study was registered at the Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, ID7237), the National Association of Statutory Health Insurance Funds (GKV Spitzenverband, ID40128) and the German clinical trial registry (Deutsche Register Klinischer Studien, ID 00006321).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Partcipating centers signed a contract for the conduction of the study with the Deutsche Arbeitsgemeinschaft niedergelassener \u00c4rzte in der Versorgung HIV-Infizierter e. V. (<i>dagn\u00e4<\/i>) e. V. located in Berlin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All co-authors have read the manuscript had sufficient time to consider changes and finally agreed to its publication in the present form.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data of the study were presented and discussed at all investigator meetings which were held twice yearly over the entire time the study was conducted in conjunction with two national HIV meetings.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Statistical analysis was conducted using Stata\/SE 15.1 (StataCorp LLC, Texas, USA).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}